Subscribe to RSS
DOI: 10.1055/s-0045-1810081
Pediatric Venous Thromboembolism: Considerations for the Interventional Radiologist
Funding KLZ acknowledges support from the NICHD Child Health Research Career Development Award Program, K12HD072245 Atlanta Pediatric Scholars Program.

Abstract
Pediatric venous thromboembolism (VTE) has seen a significant rise in prevalence coinciding with the increasing availability of complex and invasive treatments in children. While anticoagulation remains the cornerstone of VTE treatment, increasing evidence supports interventional approaches for select cases, particularly in life- or limb-threatening scenarios. Treatment strategies must be individualized, considering age-related differences in hemostasis and the higher bleeding risk associated with interventions. This remains challenging due to a dearth of pediatric-specific studies. This manuscript explores pathophysiology, risk factors, and management strategies for pediatric VTE, emphasizing both pharmacologic and interventional treatments and providing updated recommendations regarding available anticoagulant agents and VTE management paradigms in children. It highlights the potential of interventional techniques in special conditions, namely Paget–Schroetter syndrome, superior vena cava syndrome, inferior vena cava atresia, pulmonary emboli, and May–Thurner syndrome. In the absence of rigorous clinical trial data, continued multidisciplinary collaboration and standardized approaches will remain imperative for ensuring careful use of interventional procedures to achieve optimal outcomes in these young patients.
Keywords
pediatric - venous thromboembolism - pulmonary embolism - interventional radiology - anticoagulation - thrombolysis - thrombectomyPublication History
Article published online:
17 July 2025
© 2025. Thieme. All rights reserved.
Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
William Mitchell, Michael H. White, Prashant Raghavendran, Gary Woods, Karen L. Zimowski. Pediatric Venous Thromboembolism: Considerations for the Interventional Radiologist. Semin intervent Radiol ; : s00451810081.
DOI: 10.1055/s-0045-1810081
-
References
- 1 Raffini L, Huang YS, Witmer C, Feudtner C. Dramatic increase in venous thromboembolism in children's hospitals in the United States from 2001 to 2007. Pediatrics 2009; 124 (04) 1001-1008
- 2 O'Brien SH, Stanek JR, Witmer CM, Raffini L. The continued rise of venous thromboembolism across US children's hospitals. Pediatrics 2022; 149 (03) e2021054649
- 3 Andrew M, David M, Adams M. et al. Venous thromboembolic complications (VTE) in children: first analyses of the Canadian Registry of VTE. Blood 1994; 83 (05) 1251-1257
- 4 Stein PD, Kayali F, Olson RE. Incidence of venous thromboembolism in infants and children: data from the National Hospital Discharge Survey. J Pediatr 2004; 145 (04) 563-565
- 5 Mahajerin A, Croteau SE. Epidemiology and risk assessment of pediatric venous thromboembolism. Front Pediatr 2017; 5: 68
- 6 Takemoto CM, Sohi S, Desai K. et al. Hospital-associated venous thromboembolism in children: incidence and clinical characteristics. J Pediatr 2014; 164 (02) 332-338
- 7 Mammen EF. Pathogenesis of venous thrombosis. Chest 1992; 102 (Suppl. 06) 640S-644S
- 8 Chernysh IN, Nagaswami C, Kosolapova S. et al. The distinctive structure and composition of arterial and venous thrombi and pulmonary emboli. Sci Rep 2020; 10 (01) 5112
- 9 Blevins EM, Glanz K, Huang YS, Raffini L, Shinohara RT, Witmer C. A multicenter cohort study of inferior vena cava filter use in children. Pediatr Blood Cancer 2015; 62 (12) 2089-2093
- 10 Monagle P, Chan AKC, Goldenberg NA. et al. Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (Suppl. 02) e737S-e801S
- 11 Monagle P, Cuello CA, Augustine C. et al. American Society of Hematology 2018 Guidelines for management of venous thromboembolism: treatment of pediatric venous thromboembolism. Blood Adv 2018; 2 (22) 3292-3316
- 12 Monagle P, Barnes C, Ignjatovic V. et al. Developmental haemostasis. Impact for clinical haemostasis laboratories. Thromb Haemost 2006; 95 (02) 362-372
- 13 Bhat RV, Young G, Sharathkumar AA. How I treat pediatric venous thromboembolism in the DOAC era. Blood 2024; 143 (05) 389-403
- 14 Monagle P, Newall F. Management of thrombosis in children and neonates: practical use of anticoagulants in children. Hematology (Am Soc Hematol Educ Program) 2018; 2018 (01) 399-404
- 15 Witmer C, Raffini L. Treatment of venous thromboembolism in pediatric patients. Blood 2020; 135 (05) 335-343
- 16 Kiskaddon AL, Branstetter J, Williams P. et al. Intravenous direct thrombin inhibitors for acute venous thromboembolism or heparin-induced thrombocytopenia with thrombosis in children: a systematic review of the literature. Semin Thromb Hemost 2025; 51 (03) 329-334
- 17 Warad D, Rao AN, Mullikin T. et al. A retrospective analysis of outcomes of dalteparin use in pediatric patients: a single institution experience. Thromb Res 2015; 136 (02) 229-233
- 18 Young G, Lensing AWA, Monagle P. et al; EINSTEIN-Jr. Phase 3 Investigators. Rivaroxaban for treatment of pediatric venous thromboembolism. An Einstein-Jr phase 3 dose-exposure-response evaluation. J Thromb Haemost 2020; 18 (07) 1672-1685
- 19 Mann KG, Butenas S, Brummel K. The dynamics of thrombin formation. Arterioscler Thromb Vasc Biol 2003; 23 (01) 17-25
- 20 Yee DL, O'Brien SH, Young G. Pharmacokinetics and pharmacodynamics of anticoagulants in paediatric patients. Clin Pharmacokinet 2013; 52 (11) 967-980
- 21 Goldenberg NA, Kittelson JM, Abshire TC. et al; Kids-DOTT Trial Investigators and the ATLAS Group. Effect of anticoagulant therapy for 6 weeks vs 3 months on recurrence and bleeding events in patients younger than 21 years of age with provoked venous thromboembolism: the Kids-DOTT randomized clinical trial. JAMA 2022; 327 (02) 129-137
- 22 Garcia DA, Baglin TP, Weitz JI, Samama MM. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (Suppl. 02) e24S-e43S
- 23 Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (Suppl. 03) 188S-203S
- 24 Hanslik A, Kitzmüller E, Tran US. et al. Anti-activated factor II assay for monitoring unfractionated heparin in children: results of the HEARTCAT study. J Thromb Haemost 2017; 15 (01) 38-46
- 25 Davila J, Cheng D, Raffini L, Thornburg CD, Corrales-Medina FF. Characterizing the use of anticoagulants in children using the American Thrombosis and Hemostasis Network Dataset (ATHN dataset). Thromb Res 2021; 197: 84-87
- 26 Merino M, Richardson N, Reaman G. et al. FDA approval summary: dalteparin for the treatment of symptomatic venous thromboembolism in pediatric patients. Pediatr Blood Cancer 2020; 67 (12) e28688
- 27 Bauersachs RM. Fondaparinux sodium: recent advances in the management of thrombosis. J Cardiovasc Pharmacol Ther 2023 ;28:10742484221145010
- 28 Yee J, Kaide CG. Emergency reversal of anticoagulation. West J Emerg Med 2019; 20 (05) 770-783
- 29 Bennett E, Delgado-Corcoran C, Pannucci CJ, Wilcox R, Heyrend C, Faustino EV. Outcomes of prophylactic enoxaparin against venous thromboembolism in hospitalized children. Hosp Pediatr 2022; 12 (06) 617-625
- 30 Kuhle S, Eulmesekian P, Kavanagh B. et al. Lack of correlation between heparin dose and standard clinical monitoring tests in treatment with unfractionated heparin in critically ill children. Haematologica 2007; 92 (04) 554-557
- 31 Hanslik A, Kitzmüller E, Tran US. et al. Monitoring unfractionated heparin in children: a parallel-cohort randomized controlled trial comparing 2 dose protocols. Blood 2015; 126 (18) 2091-2097
- 32 Gay J, Le Beller C, Asgari R. et al. Heparin-induced thrombocytopenia in newborns: experience at a pediatric hospital and a literature review. Res Pract Thromb Haemost 2023; 7 (07) 102214
- 33 Wardrop D, Keeling D. The story of the discovery of heparin and warfarin. Br J Haematol 2008; 141 (06) 757-763
- 34 Otto CM, Nishimura RA, Bonow RO. et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. Circulation 2021; 143 (05) e35-e71
- 35 Pastori D, Menichelli D, Cammisotto V, Pignatelli P. Use of direct oral anticoagulants in patients with antiphospholipid syndrome: a systematic review and comparison of the international guidelines. Front Cardiovasc Med 2021; 8: 715878
- 36 Massicotte P, Leaker M, Marzinotto V. et al. Enhanced thrombin regulation during warfarin therapy in children compared to adults. Thromb Haemost 1998; 80 (04) 570-574
- 37 Ebell MH. Evidence-based initiation of warfarin (Coumadin). Am Fam Physician 2005; 71 (04) 763-765
- 38 Boonyawat K, O'Brien SH, Bates SM. How I treat heavy menstrual bleeding associated with anticoagulants. Blood 2017; 130 (24) 2603-2609
- 39 Peake LJ, Grover SR, Monagle PT, Kennedy AD. Effect of warfarin on menstruation and menstrual management of the adolescent on warfarin. J Paediatr Child Health 2011; 47 (12) 893-897
- 40 Hursting MJ, Dubb J, Verme-Gibboney CN. Argatroban anticoagulation in pediatric patients: a literature analysis. J Pediatr Hematol Oncol 2006; 28 (01) 4-10
- 41 Young G, Boshkov LK, Sullivan JE. et al. Argatroban therapy in pediatric patients requiring nonheparin anticoagulation: an open-label, safety, efficacy, and pharmacokinetic study. Pediatr Blood Cancer 2011; 56 (07) 1103-1109
- 42 Kiskaddon AL, Do NL, Williams P, Betensky M, Goldenberg NA. Anticoagulation with intravenous direct thrombin inhibitors in pediatric extracorporeal membrane oxygenation: a systematic review of the literature. Semin Thromb Hemost 2023; 49 (07) 756-763
- 43 Machado DS, Garvan C, Philip J. et al. Bivalirudin may reduce the need for red blood cell transfusion in pediatric cardiac patients on extracorporeal membrane oxygenation. ASAIO J 2021; 67 (06) 688-696
- 44 McMichael A, Weller J, Li X, Hatton L, Zia A, Raman L. Prospective randomized pilot study comparing bivalirudin versus heparin in neonatal and pediatric extracorporeal membrane oxygenation. Pediatr Crit Care Med 2025; 26 (01) e86-e94
- 45 Hasan RA, Pak J, Kirk CJ, Friedland-Little JM, Chandler WL. Monitoring direct thrombin inhibitors with calibrated diluted thrombin time vs activated partial thromboplastin time in pediatric patients. Am J Clin Pathol 2023; 159 (01) 60-68
- 46 Male C, Lensing AWA, Palumbo JS. et al; EINSTEIN-Jr Phase 3 Investigators. Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial. Lancet Haematol 2020; 7 (01) e18-e27
- 47 Halton J, Brandão LR, Luciani M. et al; DIVERSITY Trial Investigators. Dabigatran etexilate for the treatment of acute venous thromboembolism in children (diversity): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial. Lancet Haematol 2021; 8 (01) e22-e33
- 48 McCrindle BW, Michelson AD, Van Bergen AH. et al; UNIVERSE Study Investigators. Thromboprophylaxis for children post-fontan procedure: insights from the universe study. J Am Heart Assoc 2021; 10 (22) e021765
- 49 Moser KA, Smock KJ. Direct oral anticoagulant (DOAC) interference in hemostasis assays. Hematology (Am Soc Hematol Educ Program) 2021; 2021 (01) 129-133
- 50 Dunois C. Laboratory monitoring of direct oral anticoagulants (DOACs). Biomedicines 2021; 9 (05) 445
- 51 Rodriguez V, Stanek J, Kerlin BA, Dunn AL. Andexanet alfa versus prothrombin complex concentrates/blood products as apixaban/rivaroxaban reversal agents: a survey among pediatric hematologists. Clin Appl Thromb Hemost 2022 ;28:10760296221078842
- 52 Cuker A, Burnett A, Triller D. et al. Reversal of direct oral anticoagulants: guidance from the anticoagulation forum. Am J Hematol 2019; 94 (06) 697-709
- 53 Ross C, Kumar R, Pelland-Marcotte MC. et al. Acute management of high-risk and intermediate-risk pulmonary embolism in children: a review. Chest 2022; 161 (03) 791-802
- 54 Vedantham S. The attract trial: a step forward for evidence based DVT care. Eur J Vasc Endovasc Surg 2018; 56 (03) 320-321
- 55 Herzog E, Zavaletta V, Katz D. et al. Interventional treatment of pediatric venous thromboembolic disease. Tech Vasc Interv Radiol 2024; 27 (02) 100957
- 56 Goldenberg NA, Durham JD, Knapp-Clevenger R, Manco-Johnson MJ. A thrombolytic regimen for high-risk deep venous thrombosis may substantially reduce the risk of postthrombotic syndrome in children. Blood 2007; 110 (01) 45-53
- 57 Goldenberg NA, Donadini MP, Kahn SR. et al. Post-thrombotic syndrome in children: a systematic review of frequency of occurrence, validity of outcome measures, and prognostic factors. Haematologica 2010; 95 (11) 1952-1959
- 58 Woods GM, Kim DW, Paden ML, Viamonte HK. Thrombolysis in children: a case report and review of the literature. Front Pediatr 2022; 9: 814033
- 59 Vedantham S, Piazza G, Sista AK, Goldenberg NA. Guidance for the use of thrombolytic therapy for the treatment of venous thromboembolism. J Thromb Thrombolysis 2016; 41 (01) 68-80
- 60 Vedantham S, Grassi CJ, Ferral H. et al; Technology Assessment Committee of the Society of Interventional Radiology. Reporting standards for endovascular treatment of lower extremity deep vein thrombosis. J Vasc Interv Radiol 2009; 20 (Suppl. 07) S391-S408
- 61 Albisetti M. Thrombolytic therapy in children. Thromb Res 2006; 118 (01) 95-105
- 62 Gill AE, Patel KN. The role of interventional radiology in the treatment of acute thrombosis and chronic veno-occlusive disease in children and adolescents. Semin Roentgenol 2019; 54 (04) 324-336
- 63 Tarango C, Manco-Johnson MJ. Pediatric thrombolysis: a practical approach. Front Pediatr 2017; 5: 260
- 64 Ries M, Zenker M, Klinge J, Keuper H, Harms D. Age-related differences in a clot lysis assay after adding different plasminogen activators in a plasma milieu in vitro. J Pediatr Hematol Oncol 1995; 17 (03) 260-264
- 65 Ansah DA, Patel KN, Montegna L, Nicholson GT, Ehrlich AC, Petit CJ. Tissue plasminogen activator use in children: bleeding complications and thrombus resolution. J Pediatr 2016; 171: 67-72.e1 , 2
- 66 Albisetti M. The fibrinolytic system in children. Semin Thromb Hemost 2003; 29 (04) 339-348
- 67 Whitworth H, Amankwah EK, Betensky M. et al. Updated guidance for efficacy and safety outcomes for clinical trials in venous thromboembolism in children: communication from the ISTH SSC subcommittee on pediatric and neonatal thrombosis and hemostasis. J Thromb Haemost 2023; 21 (06) 1666-1673
- 68 Pelland-Marcotte MC, Tucker C, Klaassen A. et al. Outcomes and risk factors of massive and submassive pulmonary embolism in children: a retrospective cohort study. Lancet Haematol 2019; 6 (03) e144-e153
- 69 Biss TT, Brandão LR, Kahr WH, Chan AK, Williams S. Clinical probability score and D-dimer estimation lack utility in the diagnosis of childhood pulmonary embolism. J Thromb Haemost 2009; 7 (10) 1633-1638
- 70 Carpenter SL, Richardson T, Hall M. Increasing rate of pulmonary embolism diagnosed in hospitalized children in the United States from 2001 to 2014. Blood Adv 2018; 2 (12) 1403-1408
- 71 Wan S, Quinlan DJ, Agnelli G, Eikelboom JW. Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: a meta-analysis of the randomized controlled trials. Circulation 2004; 110 (06) 744-749
- 72 Ross CE, Shih JA, Kleinman ME, Donnino MW. Pediatric massive and submassive pulmonary embolism: a single-center experience. Hosp Pediatr 2020; 10 (03) 272-276
- 73 Dang MP, Cheng A, Garcia J. et al. Bringing PERT to pediatrics: initial experience and outcomes of a pediatric multidisciplinary pulmonary embolism response team (PERT). Chest 2025; 167 (03) 851-862
- 74 Avgerinos ED, Saadeddin Z, Abou Ali AN. et al. A meta-analysis of outcomes of catheter-directed thrombolysis for high- and intermediate-risk pulmonary embolism. J Vasc Surg Venous Lymphat Disord 2018; 6 (04) 530-540
- 75 Akam-Venkata J, Forbes TJ, Schreiber T. et al. Catheter-directed therapy for acute pulmonary embolism in children. Cardiol Young 2019; 29 (03) 263-269
- 76 Belsky J, Warren P, Stanek J, Kumar R. Catheter-directed thrombolysis for submassive pulmonary embolism in children: a case series. Pediatr Blood Cancer 2020; 67 (04) e28144
- 77 Ji D, Gill AE, Durrence WW. et al. Catheter-directed pharmacologic thrombolysis for acute submassive and massive pulmonary emboli in children and adolescents-an exploratory report. Pediatr Crit Care Med 2020; 21 (01) e15-e22
- 78 Bavare AC, Naik SX, Lin PH. et al. Catheter-directed thrombolysis for severe pulmonary embolism in pediatric patients. Ann Vasc Surg 2014; 28 (07) 1794.e1-1794.e7
- 79 Maślanka K, Zielinska N, Karauda P. et al. Congenital, acquired, and trauma-related risk factors for thoracic outlet syndrome-review of the literature. J Clin Med 2023; 12 (21) 6811
- 80 King EC, Goldman RE, Schwenke M, Sarkeshik AA. Subclavian effort thrombosis: pathophysiology, diagnosis, and management. Semin Intervent Radiol 2022; 39 (03) 304-311
- 81 Abdalla BA, Kakamad FH, Namiq HS. et al. Pediatric thoracic outlet syndrome: a systematic review with metadata. Pediatr Surg Int 2024; 40 (01) 186
- 82 Karaolanis G, Antonopoulos CN, Koutsias SG. et al. A systematic review and meta-analysis for the management of Paget-Schroetter syndrome. J Vasc Surg Venous Lymphat Disord 2021; 9 (03) 801-810.e5
- 83 Hoexum F, Hoebink M, Coveliers HME, Wisselink W, Jongkind V, Yeung KK. Management of Paget-Schroetter syndrome: a systematic review and meta-analysis. Eur J Vasc Endovasc Surg 2023; 66 (06) 866-875
- 84 Keller RE, Croswell DP, Medina GIS, Cheng TTW, Oh LS. Paget-Schroetter syndrome in athletes: a comprehensive and systematic review. J Shoulder Elbow Surg 2020; 29 (11) 2417-2425
- 85 Lee JT, Karwowski JK, Harris EJ, Haukoos JS, Olcott IV C. Long-term thrombotic recurrence after nonoperative management of Paget-Schroetter syndrome. J Vasc Surg 2006; 43 (06) 1236-1243
- 86 Brandão LR, Williams S, Kahr WH, Ryan C, Temple M, Chan AK. Exercise-induced deep vein thrombosis of the upper extremity. 2. A case series in children. Acta Haematol 2006; 115 (3–4): 221-229
- 87 Trenor III CC, Fisher JG, Khan FA. et al. Paget-Schroetter syndrome in 21 children: outcomes after multidisciplinary care. J Pediatr 2015; 166 (06) 1493-7.e1
- 88 Matos JM, Gonzalez L, Kfoury E, Echeverria A, Bechara CF, Lin PH. Outcomes following operative management of thoracic outlet syndrome in the pediatric patients. Vascular 2018; 26 (04) 410-417
- 89 Rigberg DA, Gelabert H. The management of thoracic outlet syndrome in teenaged patients. Ann Vasc Surg 2009; 23 (03) 335-340
- 90 Kumar R, Harsh K, Saini S. et al. Treatment-related outcomes in Paget-Schroetter syndrome-a cross-sectional investigation. J Pediatr 2019; 207: 226-232.e1
- 91 Talutis SD, Ulloa JG, Gelabert HA. The impact of competitive level of high school and collegiate athletes on outcomes of thoracic outlet syndrome. J Vasc Surg 2024; 79 (02) 388-396
- 92 Nadim B, Alizada S, Gupta S, Steigner ML, Menard MT, Aghayev A. Under pressure: a head-to-toe review of vascular compression syndromes. Clin Radiol 2024; 79 (10) 722-735
- 93 Teta A, Mohan J, Varghese V. et al. Iliofemoral acute deep venous thrombosis, chronic deep venous thrombosis, and May-Thurner syndrome. Interv Cardiol Clin 2025; 14 (02) 297-310
- 94 Avila L, Cullinan N, White M. et al. Pediatric May-Thurner syndrome-systematic review and individual patient data meta-analysis. J Thromb Haemost 2021; 19 (05) 1283-1293
- 95 Mickley V, Schwagierek R, Rilinger N, Görich J, Sunder-Plassmann L. Left iliac venous thrombosis caused by venous spur: treatment with thrombectomy and stent implantation. J Vasc Surg 1998; 28 (03) 492-497
- 96 Milinis K, Thapar A, Shalhoub J, Davies AH. Antithrombotic therapy following venous stenting: international Delphi consensus. Eur J Vasc Endovasc Surg 2018; 55 (04) 537-544
- 97 Warad DM, Rao AN, Bjarnason H, Rodriguez V. Clinical outcomes of May-Thurner syndrome in pediatric patients: a single institutional experience. TH Open 2020; 4 (03) e189-e196
- 98 Murphy EH, Davis CM, Journeycake JM, DeMuth RP, Arko FR. Symptomatic Ileofemoral DVT after onset of oral contraceptive use in women with previously undiagnosed May-Thurner syndrome. J Vasc Surg 2009; 49 (03) 697-703
- 99 Goldenberg NA, Branchford B, Wang M, Ray Jr C, Durham JD, Manco-Johnson MJ. Percutaneous mechanical and pharmacomechanical thrombolysis for occlusive deep vein thrombosis of the proximal limb in adolescent subjects: findings from an institution-based prospective inception cohort study of pediatric venous thromboembolism. J Vasc Interv Radiol 2011; 22 (02) 121-132
- 100 Goldman RE, Arendt VA, Kothary N. et al. Endovascular management of May-Thurner syndrome in adolescents: a single-center experience. J Vasc Interv Radiol 2017; 28 (01) 71-77
- 101 Karim S, Gayou E, Gross J. et al. Selective iliofemoral stent placement for complex pediatric cases: a decade of institutional experience. Pediatr Radiol 2024; 54 (09) 1540-1548
- 102 Bertino FJ, Hawkins CM, Woods GM. et al. Technical feasibility and clinical efficacy of iliac vein stent placement in adolescents and young adults with May-Thurner syndrome. Cardiovasc Intervent Radiol 2024; 47 (01) 45-59
- 103 Hacquebord JH, Leopold SS. In brief: the Risser classification: a classic tool for the clinician treating adolescent idiopathic scoliosis. Clin Orthop Relat Res 2012; 470 (08) 2335-2338
- 104 McBane II RD, Leadley Jr RJ, Baxi SM, Karnicki K, Wysokinski W. Iliac venous stenting: antithrombotic efficacy of PD0348292, an oral direct factor Xa inhibitor, compared with antiplatelet agents in pigs. Arterioscler Thromb Vasc Biol 2008; 28 (03) 413-418
- 105 Guo B, Chen C, Li Y. et al; POATIVES collaborative study group. Principles of optimal antithrombotic therapy for iliac venous stenting (POATIVES): a national expert-based Delphi consensus study. J Vasc Surg Venous Lymphat Disord 2024; 12 (02) 101739
- 106 Tzifa A, Marshall AC, McElhinney DB, Lock JE, Geggel RL. Endovascular treatment for superior vena cava occlusion or obstruction in a pediatric and young adult population: a 22-year experience. J Am Coll Cardiol 2007; 49 (09) 1003-1009
- 107 Nossair F, Schoettler P, Starr J. et al. Pediatric superior vena cava syndrome: an evidence-based systematic review of the literature. Pediatr Blood Cancer 2018; 65 (09) e27225
- 108 Kazanci SY, McElhinney DB, Thiagarajan R. et al. Obstruction of the superior vena cava after neonatal extracorporeal membrane oxygenation: association with chylothorax and outcome of transcatheter treatment. Pediatr Crit Care Med 2013; 14 (01) 37-43
- 109 Salavitabar A, Flyer JN, Torres AJ. et al. Transcatheter stenting of superior vena cava obstruction after pediatric heart transplantation: a single-center experience assessing risk factors and outcomes. Pediatr Transplant 2018; 22 (07) e13267
- 110 Frazer JR, Ing FF. Stenting of stenotic or occluded iliofemoral veins, superior and inferior vena cavae in children with congenital heart disease: acute results and intermediate follow up. Catheter Cardiovasc Interv 2009; 73 (02) 181-188
- 111 Ji D, Gill AE, Ermentrout RM, Hawkins CM. Thrombogenic superior vena cava syndrome from long-standing central venous access in a 5-year-old patient treated with balloon-expandable stents. J Radiol Case Rep 2018; 12 (04) 15-22
- 112 Pradhan S, Batlivala SP, Pombo LR. et al. A single-center review of clinical outcomes after transcatheter relief of superior vena cava stenosis in a pediatric and young adult population. J Soc Cardiovasc Angiogr Interv 2024; 3 (10) 102245
- 113 Bravo-Pérez C, Blanco A, Revilla N. et al; IVC Agenesis Study Group. Thrombotic risk and features of patients with inferior vena cava agenesis: a multicentre, retrospective, observational study. Lancet Haematol 2024; 11 (08) e606-e616
- 114 Verma M, Pandey NN, Ojha V, Kumar S, Ramakrishnan S. Developmental anomalies of the inferior vena cava and its tributaries: what the radiologist needs to know?. Indian J Radiol Imaging 2022; 32 (03) 355-364
- 115 Saab K, Brahmandam AS, Brackett AL. et al. Systematic review of inferior vena cava atresia. J Vasc Surg Venous Lymphat Disord 2023; 11 (06) 1253-1264
- 116 Mabud TS, Sailer AM, Swee JKY. et al. Inferior vena cava atresia: characterisation of risk factors, treatment, and outcomes. Cardiovasc Intervent Radiol 2020; 43 (01) 37-45
- 117 Pantic N, Cvetkovic M, Milin-Lazovic J. et al. Deep venous thrombosis in patients with atresia of the inferior vena cava and right kidney hypoplasia (KILT syndrome): systematic review of the literature. Vasc Med 2024; 29 (03) 320-327
- 118 de la Morena-Barrio ME, Gindele R, Bravo-Pérez C. et al. High penetrance of inferior vena cava system atresia in severe thrombophilia caused by homozygous antithrombin Budapest 3 variant: description of a new syndrome. Am J Hematol 2021; 96 (11) 1363-1373
- 119 Tufano A, López-Jiménez L, Bikdeli B. et al; RIETE Investigators. Inferior vena cava agenesis in patients with lower limb deep vein thrombosis in the RIETE registry. When and why to suspect. Int J Cardiol 2020; 305: 115-119
- 120 Oblitas CM, García-García A, Galeano-Valle F. et al. Long-term anticoagulant treatment in patients with inferior vena cava agenesis and deep vein thrombosis. Thromb Res 2020; 196: 305-307
- 121 Alexiou VG, Ntanika A, Pappas G, Vassiliou A, Palialexis K, Geroulakos G. Conservative treatment vs thrombus removal for iliofemoral vein thrombosis in patients with congenital abnormalities of the inferior vena cava: a case report and systematic review of the literature. J Thromb Thrombolysis 2022; 54 (02) 230-254
- 122 Tufano A, Cannavacciuolo F, Gianno A. et al. Inferior vena cava agenesis and deep vein thrombosis in the young: a review of the literature and local experience. Semin Thromb Hemost 2017; 43 (08) 827-835
- 123 Iarossi M, Hermans C. Direct oral anticoagulants for inferior vena cava agenesis. Clin Appl Thromb Hemost 2023 ;29:10760296231200224
- 124 Kinariwala D, Liles A, Williams DM, Khaja MS. Iliocaval reconstruction: review of technique, challenges, and outcomes. Semin Intervent Radiol 2022; 39 (05) 464-474
- 125 Cronan JC, Gill AE, Gera A, Hawkins CM. Endovascular treatment of inferior vena cava agenesis using the azygos vein. J Vasc Interv Radiol 2017; 28 (09) 1270-1271
- 126 Hung ML, Kwon D, Sudheendra D. Endovascular IVC reconstruction in an 18 year old patient with subtotal IVC atresia. EJVES Vasc Forum 2021; 52: 5-10